3 / 3
Page 21
July 18-19, 2019 | Valencia, Spain
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Asian Journal of Biomedical and Pharmaceutical Sciences
ISSN: 2249-622X | Volume 9
Pharma Summit 2019
2
nd
GLOBAL PHARMA SUMMIT
Asian J Biomed Pharmaceut Sci 2019, Volume 9
DEVELOPMENT OF FOLATE CONJUGATED SOLID LIPID NANOPARTICLE OF PACLITAXEL
FOR SELECTIVE TARGETING OF FOLATE RECEPTOR OVER EXPRESSED LUNG SQUA-
MOUS CARCINOMA CELL
Rajoriya V
and
Sushil Kumar Kashaw
Dr Hari Singh Gour University, India
C
ancer is a leading cause of death worldwide and 1.59 million deaths due to the lung cancer till 2016 as stated by World
Health Organization. Indian Council of Medical Research (ICMR) stated that India is likely to have over 17.3 lakhs new
cases of cancer and over 8.8 lakhs deaths till 2020 with cancers of breast, lung and cervix. Currently more than 10 lakhs new
patients are confirmed to have cancer on biopsy every year in India and our citizens are facing a tremendous increase in
the projected incidence of various cancers. The overall survival rate in last five years has around 17% with the presented
chemotherapy, so emphasizing the need for more effective and novel therapeutic strategies. The objective of this study is to
develop folate conjugated paclitaxel (PTX) encapsulated solid lipid nanoparticle (FSLNs) for the lung squamous carcinoma
cells targeting. It may improve targeting propensity as well as enhance bio-distribution and pharmacokinetic properties of
drugs. Solvent evaporation exploiting hot homogenization method was employed for the preparation of FSLNs. FSLNs has
characterized for particle size, polydispersity index, zeta potential, entrapment efficiency and drug loading capacity. The
FSLNs had shown particle size 231.11±2.3nm by TEM. FSLNs have shown improved entrapment efficiency and drug loading
capacity. The hemolytic study stated that FSLNs have reduced blood toxicity in comparison to PTX-SLNs and paclitaxel drug
solution (PS). The cell uptake study has shown higher accumulation of FSLNs in lung squamous carcinoma cell. Ex-vivo study
has confirmed the reduce GI50 of FSLNs in comparison to paclitaxel solution (PS) evaluated by SRB assay. A momentous
improvement of drug concentration was found in the carcinogenic squamous cells through FSLNs. The results concluded
that the FSLNs are safe, stable and potentially promising drug delivery system for lung targeting.